- Home
- SYRE vs ANAB Comparison
SYRE vs ANAB Comparison
Compare SYRE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- ANAB
- Stock Information
- Founded
- SYRE 2013
- ANAB 2005
- Country
- SYRE United States
- ANAB United States
- Employees
- SYRE N/A
- ANAB N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- ANAB Health Care
- Exchange
- SYRE Nasdaq
- ANAB Nasdaq
- Market Cap
- SYRE 1.1B
- ANAB 951.1M
- IPO Year
- SYRE 2016
- ANAB 2017
- Fundamental
- Price
- SYRE $23.56
- ANAB $35.04
- Analyst Decision
- SYRE Strong Buy
- ANAB Buy
- Analyst Count
- SYRE 6
- ANAB 11
- Target Price
- SYRE $57.60
- ANAB $57.00
- AVG Volume (30 Days)
- SYRE 1.3M
- ANAB 562.3K
- Earning Date
- SYRE 11-06-2025
- ANAB 10-31-2025
- Dividend Yield
- SYRE N/A
- ANAB N/A
- EPS Growth
- SYRE N/A
- ANAB N/A
- EPS
- SYRE N/A
- ANAB N/A
- Revenue
- SYRE N/A
- ANAB $123,164,000.00
- Revenue This Year
- SYRE N/A
- ANAB $24.36
- Revenue Next Year
- SYRE N/A
- ANAB N/A
- P/E Ratio
- SYRE N/A
- ANAB N/A
- Revenue Growth
- SYRE N/A
- ANAB 304.17
- 52 Week Low
- SYRE $10.91
- ANAB $12.21
- 52 Week High
- SYRE $40.26
- ANAB $35.77
- Technical
- Relative Strength Index (RSI)
- SYRE 70.08
- ANAB 70.65
- Support Level
- SYRE $21.88
- ANAB $33.01
- Resistance Level
- SYRE $24.02
- ANAB $35.58
- Average True Range (ATR)
- SYRE 1.62
- ANAB 1.64
- MACD
- SYRE 0.32
- ANAB -0.08
- Stochastic Oscillator
- SYRE 93.11
- ANAB 88.23
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).